Taylor Devices Inc (TAYD) 19.26 $TAYD Shares of TAYD Up

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Taylor Devices Inc (TAYD) 19.26 $TAYD

Shares of TAYD Up 28.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 21, 1:23PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 6 months, Taylor Devices has returned 28.38% as of today's recent price of $19.27.
TAYD: 19.26 (+0.30)

Taylor Devices Has Returned 27.4% Since SmarTrend Recommendation (TAYD)
Comtex SmarTrend(R) - Wed Sep 14, 1:09AM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 6 months, Taylor Devices has returned 27.45% as of today's recent price of $19.13.
TAYD: 19.26 (+0.30)

Taylor Devices Shares Up 25.0% Since SmarTrend's Buy Recommendation (TAYD)
Comtex SmarTrend(R) - Tue Sep 06, 1:35PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 5 months, Taylor Devices has returned 25.02% as of today's recent price of $18.77.
TAYD: 19.26 (+0.30)

Taylor Devices Up 25.1% Since SmarTrend Uptrend Call (TAYD)
Comtex SmarTrend(R) - Tue Aug 30, 1:00AM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 5 months, Taylor Devices has returned 25.13% as of today's recent price of $18.78.
TAYD: 19.26 (+0.30)

Taylor Devices Announces Strong Fourth Quarter And Record Full Year Results
PR Newswire - Mon Aug 29, 9:14AM CDT
Taylor Devices, Inc. (NASDAQ SmallCap: "TAYD" announced today that it had net earnings for the 4th quarter of $1,092,314, up from last year's 4th quarter profit of $886,575. Net income for the full fiscal year was an all-time record $4,208,225, and almost double last year's full fiscal year net income of $2,174,948.
TAYD: 19.26 (+0.30)

Taylor Devices Shares Up 33.8% Since SmarTrend's Buy Recommendation (TAYD)
Comtex SmarTrend(R) - Mon Aug 22, 1:21PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 5 months, Taylor Devices has returned 33.79% as of today's recent price of $20.08.
TAYD: 19.26 (+0.30)

32.9% Return Seen to Date on SmarTrend Taylor Devices Call (TAYD)
Comtex SmarTrend(R) - Fri Aug 12, 1:25PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 5 months, Taylor Devices has returned 32.91% as of today's recent price of $19.95.
TAYD: 19.26 (+0.30)

28.1% Return Seen to Date on SmarTrend Taylor Devices Call (TAYD)
Comtex SmarTrend(R) - Thu Jul 28, 1:33PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 29th, 2016 at $15.01. In approximately 4 months, Taylor Devices has returned 28.11% as of today's recent price of $19.23.
TAYD: 19.26 (+0.30)

Taylor Devices Announces Strong Second Quarter And Six Month Results
PR Newswire - Tue Jan 12, 9:13AM CST
Taylor Devices, Inc. (NASDAQ SmallCap: TAYD) announced today that it had 2nd quarter Net earnings of $924,658, up significantly from last year's 2nd quarter earnings of $504,313. Net earnings for the 1st six months were $1,934,307, also up sharply from last year's earnings of $896,619.
TAYD: 19.26 (+0.30)

71.8% Return Seen to Date on SmarTrend Taylor Devices Call (TAYD)
Comtex SmarTrend(R) - Fri Dec 11, 5:33PM CST
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 21 months, Taylor Devices has returned 71.83% as of today's recent price of $15.25.
TAYD: 19.26 (+0.30)

Uptrend Call Working As Taylor Devices Stock Rises 74.6% (TAYD)
Comtex SmarTrend(R) - Fri Dec 04, 1:15PM CST
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 21 months, Taylor Devices has returned 74.65% as of today's recent price of $15.50.
TAYD: 19.26 (+0.30)

Taylor Devices Up 74.6% Since SmarTrend Uptrend Call (TAYD)
Comtex SmarTrend(R) - Fri Dec 04, 11:58AM CST
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 21 months, Taylor Devices has returned 74.65% as of today's recent price of $15.50.
TAYD: 19.26 (+0.30)

Shares of TAYD Up 79.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 27, 9:18AM CST
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 20 months, Taylor Devices has returned 79.27% as of today's recent price of $15.91.
TAYD: 19.26 (+0.30)

Shares of TAYD Up 87.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 05, 10:26AM CST
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 20 months, Taylor Devices has returned 87.15% as of today's recent price of $16.61.
TAYD: 19.26 (+0.30)

Uptrend Call Working As Taylor Devices Stock Rises 83.1% (TAYD)
Comtex SmarTrend(R) - Wed Oct 28, 5:18PM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 19 months, Taylor Devices has returned 83.10% as of today's recent price of $16.25.
TAYD: 19.26 (+0.30)

Taylor Devices Shares Up 74.1% Since SmarTrend's Buy Recommendation (TAYD)
Comtex SmarTrend(R) - Wed Oct 21, 11:52AM CDT
SmarTrend identified an Uptrend for Taylor Devices (NASDAQ:TAYD) on March 25th, 2014 at $8.88. In approximately 19 months, Taylor Devices has returned 74.08% as of today's recent price of $15.45.
TAYD: 19.26 (+0.30)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 0

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 158

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 30

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 119

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 18

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading